Myriad Genetics is a molecular diagnostics company that focuses on developing and delivering innovative genetic testing and personalized medicine solutions. The company aims to empower healthcare providers and patients with valuable insights into genetic predispositions for various health conditions. Its comprehensive portfolio includes tests for hereditary cancer risk, pharmacogenomics, and other complex diseases, enabling informed medical decision-making and tailored treatment plans. By leveraging advanced technologies in genetics and genomics, Myriad Genetics strives to enhance patient care and improve clinical outcomes. Read More
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company’s possible violations of federal securities laws.
Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges.
The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN)
fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS, and EBITDA guidance due to weaker trends in its pharmacogenomics and hereditary cancer testing (women's health) businesses. On the other hand, MYGN significantly beat analysts' EPS and EBITDA expectations. Overall, this was a softer quarter.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
